- AEON Biopharma granted new CFO John Bencich 754,717 restricted stock units under its 2025 Employment Inducement Incentive Award Plan.
- RSUs vest over four years, with 25% vesting on each annual anniversary of March 9, 2026.
- Compensation package also includes 235,849 performance-based restricted stock units with vesting tied to a future listing-status milestone.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AEON Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604031610PRIMZONEFULLFEED9684024) on April 03, 2026, and is solely responsible for the information contained therein.
Comments